1. Signaling Pathways
  2. MAPK/ERK Pathway
  3. MAPKAPK2 (MK2)

MAPKAPK2 (MK2)

Mitogen-activated protein kinase activated protein kinase 2; MAP kinase activated protein kinase 2; MAPK activated protein kinase 2; MAPKAP kinase 2

MAP kinase-activated protein kinase 2 (MAPKAPK2) is an enzyme that in humans is encoded by the MAPKAPK2 gene. MAPKAP kinase-2 (MK2) is originally identified by its phosphorylation of glycogen synthase at serine-7 and the corresponding serine in a peptide (GS peptide-1) modelled after the N-terminus of glycogen synthase.

MAPKAP kinase-2 is a novel protein kinase activated by mitogen-activated protein kinase. This MAP kinase activated protein kinase, termed MAPKAP kinase-2, is distinguished from S6 kinase-II (MAPKAP kinase-1) by its response to inhibitors, lack of phosphorylation of S6 peptides and amino acid sequence.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N0591R
    Dehydrocostus Lactone (Standard)
    Inhibitor
    Dehydrocostus Lactone (Standard) ((-)-Dehydrocostus lactone (Standard)) is the analytical standard of Dehydrocostus Lactone (HY-N0591). This product is intended for research and analytical applications. Dehydrocostus Lactone is a natural sesquiterpene that can be isolated from Saussurea lappa. Dehydrocostus Lactone has multiple activities such as anti-inflammatory, antibacterial, anti-tumor, and immunomodulatory effects. Dehydrocostus Lactone has an MIC of 2 µg/mL against Mycobacterium tuberculosis. Dehydrocostus Lactone can also inhibit the killing activity of cytotoxic T lymphocytes and induce apoptosis in tumor cells.
    Dehydrocostus Lactone (Standard)
  • HY-P10796
    YARA peptide
    Inhibitor
    YARA peptide, a cell-penetrating peptide, is a MK2 inhibitor. YARA-loaded nanoparticles decreases the levels of inflammatory cytokines (IL-1β, IL-6, and TNF-α) in an ex vivo skin culture model. YARA peptide is promising for research of atopic dermatitis (AD).
    YARA peptide
  • HY-16129A
    CBP-501 acetate
    Inhibitor 99.75%
    CBP-501 acetate, a cell-permeable calmodulin-binding peptide and a G2-abrogating drug candidate, inhibits the activity of multiple Ser216-specific kinases, such as MAPKAP-K2, C-Tak1, CHK1 and CHK2, with IC50 values of 0.9 μM, 1.4 μM 3.4 μM and 6.5 μM, respectively. CBP-501 acetate is used for various types of cancer.
    CBP-501 acetate
  • HY-168841
    p38α-MK2-IN-1
    Inhibitor
    p38α-MK2-IN-1 (Compound 36) is a p38α-MK2 complex inhibitor (IC50: 5 nM). p38α-MK2-IN-1 has a robust inflammation inhibitory effect and joint repair ability.
    p38α-MK2-IN-1
  • HY-172807
    p38α-IN-9
    Inhibitor
    p38α-IN-9 (Compound 2015) is a p38α inhibitor and blocks p38α’s enzymatic activity with an IC50 lower than 20 nM. p38α-IN-9 inhibits MK2T334 phosphorylation. p38α-IN-9 activates Cdc25b and Cdc25c and simultaneously inactivates Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy and DNA damage. p38α-IN-9 Inhibits colorectal cancer (CRC) metastasis.
    p38α-IN-9
  • HY-175809
    SRT6
    Inhibitor
    SRT6 is a CD44 inhibitor. SRT6 exerts antiproliferative activity in CD44+ breast cancer and lung cancer cells. SRT6 inhibits CD44-associated SRC kinase, as well as EGFR, ERBB2, ERBB4, MAP3K10 and MAPKAPK2. SRT6 can be used for the research of breast cancer and lung cancer.
    SRT6
  • HY-179237
    MK2-IN-8
    Inhibitor
    MK2-IN-8 (Compound 42) is a covalent MK2 kinase inhibitor. MK2-IN-8 forms a unique covalent bond with the catalytic lysine, thereby demonstrating that the fluorosulfonate can effectively target the catalytic lysine in kinases.
    MK2-IN-8
  • HY-N2393S
    Kukoamine B-d5 dihydrochloride
    Inhibitor
    Kukoamine B, a spermine alkaloid, is a potent dual LPS and CpG DNA inhibitor with Kd values of 1.23 µM and 0.66 µM, respectively. Kukoamine B exerts anti-inflammatory, anti-diabetic, anti-oxidant, anti-osteoporotic and neuroprotective effects. Kukoamine B has the potential for the study of sepsis. .
    Kukoamine B-d<sub>5</sub> dihydrochloride
  • HY-N2393R
    Kukoamine B (Standard)
    Inhibitor
    Kukoamine B (Standard) is the analytical standard of Kukoamine B. This product is intended for research and analytical applications. Kukoamine B, a spermine alkaloid, is a potent dual LPS and CpG DNA inhibitor with Kd values of 1.23 µM and 0.66 µM, respectively. Kukoamine B exerts anti-inflammatory, anti-diabetic, anti-oxidant, anti-osteoporotic and neuroprotective effects. Kukoamine B has the potential for the study of sepsis.
    Kukoamine B (Standard)
  • HY-12358A
    Tpl2 Kinase Inhibitor 1 hydrochloride
    Inhibitor
    Tpl2 Kinase Inhibitor 1 hydrochloride is a 3-pyridylmethylamino analog, and is a selective Tpl2 inhibitor (IC50=50 nM). Tpl2 consists of COT kinase and MAP3K8. Tpl2 Kinase Inhibitor 1 hydrochloride plays an important role in the regulation of the inflammatory response and the progression of some cancers.
    Tpl2 Kinase Inhibitor 1 hydrochloride
  • HY-162700
    MK2-IN-6
    Inhibitor
    MK2-IN-6 (Compound 11) is a potent and selective irreversible MK2 inhibitor with an IC50 value of 2.3 nM. MK2-IN-6 inhibits MK2 kinase activity, achieving prolonged MK2 signaling suppression and reducing pathological inflammatory cytokines in macrophages. MK2-IN-6 inhibits the M2-like protumor phenotype of macrophages both in vitro and in vivo, which is proming for research of colorectal cancer.
    MK2-IN-6
  • HY-107427R
    PF-3644022 (Standard)
    Inhibitor
    PF-3644022 (Standard) is the analytical standard of PF-3644022 (HY-107427). This product is intended for research and analytical applications. PF-3644022 is a potent, selective, orally active and ATP-competitive MAPKAPK2 (MK2) inhibitor with an IC50 of 5.2 nM and a Ki of 3 nM. PF-3644022 also inhibits MK3 and p38 regulated/activated Kinase (PRAK) with IC50s of 53 nM and 5.0 nM, respectively. PF-3644022 potently inhibits TNFα production and has anti-inflammatory effect.
    PF-3644022 (Standard)
  • HY-108643R
    CMPD1 (Standard)
    Inhibitor
    CMPD1 (Standard) is the analytical standard of CMPD1 (HY-108643). This product is intended for research and analytical applications. CMPD1 is a selective and non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation inhibitor with apparent Ki (Kiapp) of 330 nM.
    CMPD1 (Standard)
Cat. No. Product Name / Synonyms Application Reactivity